Bibliography
- The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491(7422):56-65
- Abecasis GR, Altshuler D, Auton A, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467(7319):1061-73
- Coventry A, Bull-Otterson LM, Liu X, et al. Deep resequencing reveals excess rare recent variants consistent with explosive population growth. Nat Commun 2010;1:131
- Nelson MR, Wegmann D, Ehm MG, et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 2012;337(6090):100-4
- Tennessen JA, Bigham AW, O'Connor TD, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012;337(6090):64-9
- Fu W, O'Connor TD, Jun G, et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 2013;493(7431):216-20
- Casals F, Hodgkinson A, Hussin J, et al. Whole-exome sequencing reveals a rapid change in the frequency of rare functional variants in a founding population of humans. PLoS Genet 2013;9(9):e1003815
- Li Y, Vinckenbosch N, Tian G, et al. Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet 2010;42(11):969-72
- Marth GT, Yu F, Indap AR, et al. The functional spectrum of low-frequency coding variation. Genome Biol 2011;12(9):R84
- Agarwala V, Flannick J, Sunyaev S, GoT2D Consortium, Altshuler D. Evaluating empirical bounds on complex disease genetic architecture. Nat Genet 2013;45(12):1418-27
- Madian AG, Wheeler HE, Jones RB, Dolan ME. Relating human genetic variation to variation in drug responses. Trends Genet 2012;28(10):487-95
- Evrard A, Mbatchi L. Genetic polymorphisms of drug metabolizing enzymes and transporters: the long way from bench to bedside. Curr Top Med Chem 2012;12(15):1720-9
- Wei C-Y, Lee M-TM, Chen Y-T. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum Mol Genet 2012;21(R1):R58-65
- Ni X, Zhang W, Huang RS. Pharmacogenomics discovery and implementation in genome-wide association studies era. Wiley Interdiscip Rev Syst Biol Med 2013;5(1):1-9
- Gough AC, Miles JS, Spurr NK, et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990;347(6295):773-6
- Kagimoto M, Heim M, Kagimoto K, et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990;265(28):17209-14
- Wright GEB, Niehaus DJH, Drögemöller BI, et al. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 2010;74(4):340-50
- Drögemöller BI, Wright GEB, Niehaus DJH, et al. Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 2010;11(8):1095-103
- Drögemöller B, Plummer M, Korkie L, et al. Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Genet 2013;4:17
- Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 2009;3(2):169-90
- Gaedigk A, Gotschall RR, Forbes NS, et al. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999;9(6):669-82
- De Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 2006;10(3):135-51
- Gaedigk A, Bhathena A, Ndjountché L, et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J 2005;5(3):173-82
- Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138(1):103-41
- CPIC Gene-Drug Pairs [PharmGKB]. Available from: https://www.pharmgkb.org/page/cpicGeneDrugPairs [Last accessed 21 January 2014]
- DPWG: Dutch Pharmacogenetics Working Group [PharmGKB]. Available from: https://www.pharmgkb.org/page/dpwg [Last accessed 21 January 2014]
- Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94(3):317-23
- Scott SA, Sangkuhl K, Gardner EE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011;90(2):328-32
- Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014. [Epub ahead of print]
- Hicks JK, Swen JJ, Thorn CF, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013;93(5):402-8
- Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90(4):625-9
- Sagreiya H, Sagrieya H, Berube C, et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics 2010;20(7):407-13
- Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011;89(3):464-7
- Drögemöller BI, Wright GEB, Niehaus DJH, et al. Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment. Pharmacogenet Genomics 2013;23(12):666-74
- Drögemöller BI, Wright GEB, Niehaus DJH, et al. Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics 2011;12(12):1717-28
- Dai D-P, Xu R-A, Hu L-M, et al. CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J 2014;14(1):85-92
- Qian J-C, Xu X-M, Hu G-X, et al. Genetic variations of human CYP2D6 in the Chinese Han population. Pharmacogenomics 2013;14(14):1731-43
- Jin T-B, Ma L-F, Zhang J-Y, et al. Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population. Gene 2013;527(1):360-5
- Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002;72(1):76-89
- CYP2C9. Available from: http://www.cypalleles.ki.se/cyp2c9.htm [Last accessed 21 January 2014]
- CYP2C19. Available from: http://www.cypalleles.ki.se/cyp2c19.htm [Last accessed 21 January 2014]
- CYP2D6. Available from: http://www.cypalleles.ki.se/cyp2d6.htm [Last accessed 21 January 2014]
- Table of TPMT alleles. Available from: http://www.imh.liu.se/tpmtalleles/tabell-over-tpmt-alleler2?l=en [Last accessed 21 January 2014]
- UGT1A1 allele nomenclature. Available from: http://www.pharmacogenomics.pha.ulaval.ca/files/content/sites/pharmacogenomics/files/Nomenclature/UGT1A/UGT1A1.htm [Last accessed 21 January 2014]
- Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available from: http://www.cypalleles.ki.se/ [Last accessed 21 January 2014]
- Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry 2013;25(5):534-53
- Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369(1):23-37
- CYP2D6[Title] - PubMed - NCBI. Available from: http://www.ncbi.nlm.nih.gov/pubmed?term=CYP2D6%5BTitle%5D [Last accessed 21 January 2014]
- Ensembl genome browser 72: homo sapiens - Gene summary - Gene: CYP2D6 (ENSG00000100197). Available from: http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100197;r=22:42522501-42526908 [Last accessed 21 January 2014]
- Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83(2):234-42
- DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2001;43(5):491-8
- SeattleSeq Variation Annotation [Internet]. Available from: http://snp.gs.washington.edu/SeattleSeqAnnotation137/ [Last accessed 21 January 2014]
- Major E, Rigó K, Hague T, et al. HLA typing from 1000 genomes whole genome and whole exome illumina data. PloS One 2013;8(11):e78410
- Yeo KR, Kenny JR, Rostami-Hodjegan A. Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. Eur J Clin Pharmacol 2013;69(6):1311-20
- Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013;14(10):703-18
- Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet 2010;375(9725):1525-35
- Altimari A, de Biase D, De Maglio G, et al. 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. OncoTargets Ther 2013;6:1057-64
- Oetjens MT, Denny JC, Ritchie MD, et al. Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Pharmacogenomics 2013;14(7):735-44
- PGRN: Network-wide Projects. Available from: http://pgrn.org/display/pgrnwebsite/Network-wide+Projects [Last accessed 21 January 2014]
- Tabor HK, Berkman BE, Hull SC, Bamshad MJ. Genomics really gets personal: how exome and whole genome sequencing challenge the ethical framework of human genetics research. Am J Med Genet A 2011;55A(12):2916-24
- Brothers KB, Langanke M, Erdmann P. Implications of the incidentalome for clinical pharmacogenomics. Pharmacogenomics 2013;14(11):1353-62
- Wright GE, Koornhof PG, Adeyemo AA, Tiffin N. Ethical and legal implications of whole genome and whole exome sequencing in African populations. BMC Med Ethics 2013;14(1):21
- Pelleymounter LL, Moon I, Johnson JA, et al. A novel application of pattern recognition for accurate SNP and indel discovery from high-throughput data: targeted resequencing of the glucocorticoid receptor co-chaperone FKBP5 in a Caucasian population. Mol Genet Metab 2011;104(4):457-69
- GATK | Best Practices. Available from: http://www.broadinstitute.org/gatk/guide/topic?name=best-practices [Last accessed 21 January 2014]
- ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011;9(4):e1001046
- Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012;22(9):1790-7
- De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269(22):15419-22
- Axiom® Exome Genotyping Arrays | Affymetrix. Available from: http://www.affymetrix.com/estore/browse/products.jsp?productId=prod570018#1_1 [Last accessed 21 January 2014]
- Infinium HumanExome BeadChip Kit. Available from: http://www.illumina.com/products/infinium_humanexome_beadchip_kit.ilmn?scid=2011017PR2 [Last accessed 21 January 2014]
- Warnich L, Drögemöller BI, Pepper MS, et al. Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation. Curr Pharmacogenomics Pers Med 2011;9(3):191-207
- Montané Jaime LK, Lalla A, Steimer W, Gaedigk A. Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants. Pharmacogenomics 2013;14(3):261-76
- Fohner A, Muzquiz LI, Austin MA, et al. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics 2013;23(8):403-14
- Raimundo S, Toscano C, Klein K, et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 2004;76(2):128-38
- Contreras AV, Monge-Cazares T, Alfaro-Ruiz L, et al. Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican Mestizos. Pharmacogenomics 2011;12(5):745-56
- Fernald GH, Capriotti E, Daneshjou R, et al. Bioinformatics challenges for personalized medicine. Bioinformatics 2011;27(13):1741-8
- Cooper GM, Shendure J. Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data. Nat Rev Genet 2011;12(9):628-40
- Patnala R, Clements J, Batra J. Candidate gene association studies: a comprehensive guide to useful in silico tools. BMC Genet 2013;14(1):39
- Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4(7):1073
- Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7(4):248-9
- Cooper GM, Stone EA, Asimenos G, et al. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res 2005;15(7):901-13
- Hao D, Xiao P, Chen S. Phenotype prediction of nonsynonymous single nucleotide polymorphisms in human phase II drug/xenobiotic metabolizing enzymes: perspectives on molecular evolution. Sci China Life Sci 2010;53(10):1252-62
- Panoutsopoulou K, Tachmazidou I, Zeggini E. In search of low-frequency and rare variants affecting complex traits. Hum Mol Genet 2013;22(R1):R16-21
- Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010;11(4):241-6
- Moore CB, Wallace JR, Frase AT, et al. BioBin: a bioinformatics tool for automating the binning of rare variants using publicly available biological knowledge. BMC Med Genomics 2013;6(Suppl 2):S6
- Zuk O, Schaffner SF, Samocha K, et al. Searching for missing heritability: designing rare variant association studies. Proc Natl Acad Sci USA 2014;111(4):E455-64
- Ramirez AH, Shaffer CM, Delaney JT, et al. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J 2013;13(4):325-9
- Zhou S-F, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008;9(8):738-84
- Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 2013;93(4):324-5
- Korf BR, Rehm HL. New approaches to molecular diagnosis. JAMA 2013;309(14):1511-21
- Altman RB, Whirl-Carrillo M, Klein TE. Challenges in the pharmacogenomic annotation of whole genomes. Clin Pharmacol Ther 2013;94(2):211-13
- Zhou K, Pearson ER. Insights from genome-wide association studies of drug response. Annu Rev Pharmacol Toxicol 2013;53:299-310
- Shah RR, Shah DR. Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol 2012;74(4):698-721
- Howland RH. Future prospects for pharmacogenetics in the quest for personalized medicine. J Psychosoc Nurs Ment Health Serv 2012;50(12):13-16
- Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther 2012;92(6):727-36
- Russell C, Rahman A, Mohammed AR. Application of genomics, proteomics and metabolomics in drug discovery, development and clinic. Ther Deliv 2013;4(3):395-413
- Wang L. Pharmacogenomics: a systems approach. Wiley Interdiscip Rev Syst Biol Med 2010;2(1):3-22
- Hicks JK, Crews KR, Hoffman JM, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 2012;92(5):563-6
- Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007;81(4):557-66
- Introduction - ClinVar - NCBI. Available from: http://www.ncbi.nlm.nih.gov/clinvar/intro/ [Last accessed 21 January 2014]
- Urban TJ. Race, ethnicity, ancestry, and pharmacogenetics. Mt Sinai J Med 2010;77(2):133-9